Nicotine e-cigarettes outperform patches and gum for quitting smoking

Researchers have found that nicotine e-cigarettes help more smokers quit than traditional nicotine replacement therapies like patches and gum. A review of 14 systematic studies from 2014 to 2023 shows consistent high-quality evidence favoring nicotine vapes. The findings highlight gaps in research on long-term risks and comparisons to other treatments.

A team led by Dr. Angela Difeng Wu from the University of Oxford's Nuffield Department of Primary Care Health Sciences analyzed 14 systematic reviews on smoking cessation methods. The highest-quality studies consistently demonstrated higher quit rates with nicotine e-cigarettes compared to nicotine patches, gum, lozenges, non-nicotine e-cigarettes, and behavioral support programs alone. Lower-quality research showed more mixed results, but the strongest evidence supports nicotine e-cigarettes as more effective. The work, published in the journal Addiction, was funded by Cancer Research UK. Dr. Wu stated, 'We hope this overview and Evidence and Gap Map can lay to rest some claims that evidence is mixed regarding the impacts of nicotine e-cigarettes on smoking abstinence. In fact, the evidence is clear and consistent across all of the meta-analyses we consulted: e-cigarettes are effective at helping people stop smoking.' Researchers created an Evidence and Gap Map to identify research needs. No high-quality reviews compare nicotine e-cigarettes to cytisine, bupropion, or nicotine pouches, and evidence against varenicline comes from just one small, high-bias study. Data on serious adverse events remains uncertain, and most studies focus on high-income countries. The authors call for more research on risks and diverse populations.

Relaterte artikler

Drug commissioner Hendrik Streeck at press conference urging ban on sweet-flavored e-cigarettes to safeguard youth from addiction.
Bilde generert av AI

Drug commissioner Streeck calls for ban on sweet flavors in e-cigarettes

Rapportert av AI Bilde generert av AI

The federal government's drug commissioner, Hendrik Streeck, advocates for banning sweet flavors in e-cigarettes to protect young people. He criticizes the marketing as an addiction strategy and welcomes planned bans on 13 ingredients. Addiction researcher Heino Stöver, however, considers the measures unjustified.

Law 2354 of 2024 aims to regulate nicotine electronic systems and similar products, but its implementation faces significant delays. Two years after promulgation, key provisions like mandatory labeling and advertising bans remain unenforced. This allows uncontrolled circulation of vapes among teens, per Ministry of Justice data.

Rapportert av AI

China's State Tobacco Monopoly Administration released a draft policy on Thursday to reduce excess capacity in the e-cigarette sector and tighten enforcement of production and export standards. This follows a State Council opinion earlier this month that imposed stricter oversight on e-cigarettes and nicotine pouches.

Et nytt studie fra Universitetet i Göteborg viser at tirzepatid, det aktive virkestoffet i diabetes- og vekttapsmedisinen Mounjaro, reduserer alkoholforbruk og tilbakefalls-lignende atferd hos rotter og mus. Dette bygger på tidligere forskning på semaglutid i Ozempic og Wegovy, som demper alkoholforbruk hos mennesker. Forskere håper på lignende effekter hos pasienter med alkoholavhengighet.

Rapportert av AI

A new review of clinical trials suggests that psychedelics like psilocybin are effective for treating depression but offer no advantage over traditional antidepressants. Researchers accounted for the challenge of blinding in psychedelic studies, where participants can often tell if they received the drug. The findings indicate similar outcomes when compared to unblinded antidepressant trials.

British American Tobacco is shutting down its Heidelberg manufacturing plant in South Africa, leading to 230 job losses, as it shifts to importing cigarettes amid a booming illicit trade. At the same time, the company is continuing an aggressive share buyback program in London to reward shareholders. Workers and experts point to government inaction on illegal cigarettes as a key factor in the decline.

Rapportert av AI

A comprehensive review of clinical trials suggests that cannabis products high in THC may provide modest, short-term relief for chronic pain, especially neuropathic types, but with notable side effects. In contrast, CBD-dominant products offer no clear advantages. Researchers call for more long-term studies to assess safety and efficacy.

 

 

 

Dette nettstedet bruker informasjonskapsler

Vi bruker informasjonskapsler for analyse for å forbedre nettstedet vårt. Les vår personvernerklæring for mer informasjon.
Avvis